Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Operating activities
Net loss	$ (146,234,000)	$ (202,847,000)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization	1,654,000	1,726,000
Stock-based compensation expense	26,729,000	28,479,000
Write-off of prepaid manufacturing services related to the termination of CHS-2020		3,210,000
Non-cash interest expense from amortization of debt discount & issuance costs	4,677,000	2,064,000
Upfront and option payments to Junshi Biosciences	35,000,000	136,000,000
Loss on debt extinguishment	6,222,000
Other non-cash adjustments, net	1,208,000	1,896,000
Changes in operating assets and liabilities:
Trade receivables, net	7,327,000	15,243,000
Inventory	(14,203,000)	(3,860,000)
Prepaid manufacturing	6,490,000	2,335,000
Other prepaid, current and non-current assets	(6,223,000)	(3,556,000)
Accounts payable	1,423,000	(773,000)
Accrued rebates, fees and reserves	(14,480,000)	2,229,000
Accrued compensation	(5,086,000)	(7,428,000)
Accrued and other current and non-current liabilities	(8,586,000)	26,461,000
Net cash (used in) provided by operating activities	(104,082,000)	1,179,000
Investing activities
Purchases of property and equipment	(1,495,000)	(560,000)
Purchases of investments in marketable securities		(140,330,000)
Proceeds from maturities of investments in marketable securities		15,000,000
Upfront and option payments to Junshi Biosciences	(35,000,000)	(136,000,000)
Net cash used in investing activities	(36,495,000)	(261,890,000)
Financing activities
Proceeds from 2027 Term Loans, net of debt discount & issuance costs	191,190,000
Proceeds from issuance of common stock to Junshi Biosciences, net of issuance costs		40,903,000
Proceeds from issuance of common stock upon exercise of stock options	552,000	8,446,000
Proceeds from purchase under the employee stock purchase plan	1,655,000	1,985,000
Taxes paid related to net share settlement of RSUs	(3,300,000)	(1,730,000)
Repayment of 2022 Convertible Notes and premiums	(109,000,000)
Repayment of 2025 Term Loan, premiums and exit fees	(81,750,000)
Other financing activities	(481,000)	(313,000)
Net cash (used in) provided by financing activities	(1,134,000)	49,291,000
Net decrease in cash, cash equivalents and restricted cash	(141,711,000)	(211,420,000)
Cash, cash equivalents and restricted cash at beginning of period	417,635,000	541,598,000
Cash, cash equivalents and restricted cash at end of period	$ 275,924,000	$ 330,178,000